Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918246 | 0.85 | POLB (0.32) | DHFRALDH1A1HTR2COPRM1OPRD1 | |
| SCHEMBL3921132 | 0.80 | — | — | |
| SCHEMBL4985791 | 0.78 | OPRM1 (0.34) | DHFROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3921926 | 0.74 | SOAT1 (0.31) | — | |
| SCHEMBL6284322 | 0.73 | CTSL (0.38) | ALDH1A1TP53OPRM1OPRL1BACE1 | |
| SCHEMBL3917771 | 0.73 | LMNA (0.35) | SIGMAR1 | |
| SCHEMBL974679 | 0.69 | TDP1 (0.38) | ALDH1A1TP53 | |
| SCHEMBL7149546 | 0.69 | HRH3 (0.32) | DHFROPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL4982694 | 0.67 | OPRM1 (0.32) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4985585 | 0.65 | OPRM1 (0.34) | OPRM1OPRD1OPRK1OPRL1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572869-B2 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | CIBA SPECIALTY CHEMICALS CORP. (US) | 2009-08-11 | — | — | US | claimed |
| US-20080015276-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | NESVADBA PETER | 2008-01-17 | — | — | US | claimed |
| US-20040082742-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | CIBA SPECIALTY CHEMICALS CORP. | 2004-04-29 | — | — | US | claimed |
| EP-1343827-A1 | N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, THEIR CORRESPONDING N-OXIDES AND CONTROLLED RADICAL POLYMERIZATION THEREWITH | Ciba SC Holding AG (CH) | 2003-09-17 | — | — | EP | claimed |
| WO-2002048205-A1 | N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, THEIR CORRESPONDING N-OXIDES AND CONTROLLED RADICAL POLYMERIZATION THEREWITH | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-06-20 | — | — | WO | claimed |
| EP-1873199-A1 | In-can stabilizers | Ciba Specialty Chemicals Holding Inc. (CH) | 2008-01-02 | — | — | EP | disclosed |
| US-7288613-B2 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding N-oxides and controlled radical polymerization therewith | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070225397-A1 | In-Can Stabilizers | CIBA SPECIALTY CHEMICALS CORP. | 2007-09-27 | — | — | US | disclosed |
| US-20060149011-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding N-oxides and controlled radical polymerization therewith | NESVADBA PETER | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149011-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding N-oxides and controlled radical polymerization therewith | ALKBH2, ALKBH3, ALKBH5 | DHFR 798/4885ALDH1A1 369/4885TP53 4814/4885 |
| US-20080015276-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | ALKBH2, ALKBH3, ALKBH5 | DHFR 685/4885ALDH1A1 361/4885TP53 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.